Clinically symptomatic respiratory illness

There is 1 paper on clinically symptomatic respiratory illness in aging research: 1 trial in people.

Disease

1 paper studies it2 findings

See all 1 papers on clinically symptomatic respiratory illness

  • Human trial1

Interventions

1

Dactolisib

no changein humans1OR 1

1 study
  1. Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (OR 1·07 [95% CI 0·80–1·42]).

    “In the full analysis set, RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness, the primary endpoint of the trial”

    Human trial16 weeksn = 1,024

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

  2. Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (phase 3 trial) (26% vs 25%; OR 1·07 (90% CI 0·80-1·42); p=0·65).

    “RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness”

    Human trialphase 3 trial10 mg once daily16 weeksn = 1,024

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

More on Dactolisib

Latest